Abstract 15632: Left Atrial Stiffness Calculated by Left Atrial Strain is a Feasible Marker for Risk Stratification and Long Term Prognosis in Patients With Heart Failure
Introduction: It was reported that left atrial remodeling is occurred in patients with heart failure (HF), and increased left atrial volume index (LAVI) is a powerful predictor for poor prognosis of HF. Recently, it was reported that left atrial stiffness (LAS) reflects pulmonary capillary wedge pressure non-invasively. However, it remains to be determined whether LAS is useful for predicting poor prognosis in patients with HF.
Hypothesis: We hypothesized that LAS can predict poor prognosis in patients with HF.
Methods: We performed transthoracic echocardiography at discharge in 149 consecutive patients (male 94, 71 ± 13 years old) who hospitalized for HF and were prospectively followed up. There were 46 cardiac events (45%) including cardiac death or rehospitalization for HF during a median follow up period of 381 days (range 37-1438 days). LAS was calculated calculated by the early mitral inflow velocity divided by the early diastolic annular velocity (E/e’) and peak systolic left atrial strain (S-LAs), as previously reported.
Results: There were no significant differences in prevalence of atrial fibrillation, left ventricular end-diastolic dimension and ejection fraction between patients with and without cardiac events. LAS and LAVI were significantly higher in patients with cardiac events than in those without (LAS, median 2.40 vs. 0.88, p<0.01; LAVI, mean 78 vs. 58 ml/m2, p<0.01). The multivariate Cox proportional hazard analysis revealed that LAS and LAVI were independent predictors for cardiac events. Kaplan-Meier analysis showed that patients with high LAS (median 1.13 < ) and high LAVI (median 60 ml/m2 < ) showed the highest cardiac event rate, and even in patients with low LAVI (60 ml/ m2), LAS could successfully risk stratify patients for cardiac events (Figure).
Conclusion: LAS may be a feasible marker for cardiac prognosis in patients with HF.
Author Disclosures: H. Tamura: None. T. Watanabe: None. G. Yamaura: None. N. Hashimoto: None. M. Wanezaki: None. S. Nishiyama: None. T. Arimoto: None. H. Takahashi: None. T. Shishido: None. T. Yamanaka: None. T. Miyamoto: None. I. Kubota: None.
- © 2016 by American Heart Association, Inc.